IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence

Status:	Recruiting
Conditions:	HIV / AIDS, HIV / AIDS
Therapuetic Areas:	Immunology / Infectious Diseases
Healthy:	No
Age Range:	Any
Updated:	7/28/2018
Start Date:	February 2015
End Date:	March 2023
Contact:	Anne Coletti, MS
Email:	acoletti@fhi360.org
Phone:	919-544-7040

IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence

IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older,
who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer,
hematopoietic disease, or other underlying disease.

Inclusion Criteria:

- Confirmed HIV-1 infection

- 12 months of age or older

- Willing to provide written informed consent

- Pre-Transplant Cohort: Underlying disease appropriate for stem cell transplant, as
determined by the transplant team as part of standard of care.

- Pre-Transplant Cohort: Availability of an appropriately matched (as determined by the
transplant center) CCR5Δ32 cord blood unit (homozygous or heterozygous) and intention
to proceed with transplantation. NOTE: Double cord transplants are allowed. If a
double cord is used, at least one cord blood unit should be CCR5∆32 (homozygous or
heterozygous).

- Pre-Transplant Cohort: Received a CCR5Δ32 homozygous cord blood or bone marrow
transplant within the last two years.

Exclusion Criteria:

• Received, or planning to receive, more than one CCR5Δ32 homozygous cord blood or bone
marrow transplant.

We found this trial at

sites

Weill Cornell Uptown Clinical Research Site (7803)

New York, New York

Principal Investigator: Koen van Besien, MD

Phone: 212-746-7134

from

New York, NY